1386 related articles for article (PubMed ID: 22748912)
1. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
2. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).
Brookman-May SD; May M; Shariat SF; Novara G; Zigeuner R; Cindolo L; De Cobelli O; De Nunzio C; Pahernik S; Wirth MP; Longo N; Simonato A; Serni S; Siracusano S; Volpe A; Morgia G; Bertini R; Dalpiaz O; Stief C; Ficarra V; ; ;
BJU Int; 2013 Nov; 112(7):909-16. PubMed ID: 23890378
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
[TBL] [Abstract][Full Text] [Related]
4. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
5. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
[TBL] [Abstract][Full Text] [Related]
6. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
7. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
9. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
10. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
[TBL] [Abstract][Full Text] [Related]
11. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of the clinical-pathological predictive factors in force in chromophobe renal cell cancer].
Pardo P; Rodríguez-Faba O; Palou J; Algaba F; Breda A; Esquena S; Villavicencio H
Actas Urol Esp; 2012 Oct; 36(9):527-31. PubMed ID: 22365081
[TBL] [Abstract][Full Text] [Related]
13. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
14. Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma.
Bertini R; Roscigno M; Freschi M; Strada E; Angiolilli D; Petralia G; Matloob R; Sozzi F; Capitanio U; Da Pozzo LF; Colombo R; Guazzoni G; Cremonini A; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):358-65. PubMed ID: 21640483
[TBL] [Abstract][Full Text] [Related]
15. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.
Kim SP; Weight CJ; Leibovich BC; Thompson RH; Costello BA; Cheville JC; Lohse CM; Boorjian SA
Urology; 2011 Nov; 78(5):1101-6. PubMed ID: 21903243
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
[TBL] [Abstract][Full Text] [Related]
18. Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma.
May M; Brookman-Amissah S; Kendel F; Knoll N; Roigas J; Hoschke B; Miller K; Gilfrich C; Pflanz S; Gralla O
Int J Urol; 2009 Jul; 16(7):616-21. PubMed ID: 19456988
[TBL] [Abstract][Full Text] [Related]
19. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Blute ML; Amling CL; Bryant SC; Zincke H
Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
[TBL] [Abstract][Full Text] [Related]
20. Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.
Sun M; Bianchi M; Hansen J; Abdollah F; Trinh QD; Lughezzani G; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
Int J Urol; 2013 Apr; 20(4):372-80. PubMed ID: 23039208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
